Cargando…
Clinical effects of wasabi extract containing 6-MSITC on myalgic encephalomyelitis/chronic fatigue syndrome: an open-label trial
BACKGROUND: Wasabi (Eutrema japonicum) is a common pungent spice used in Japan. 6-Methylsulfinylhexyl isothiocyanate (6-MSITC) found in the rhizome of wasabi has been shown to have anti-inflammatory and antioxidant effects, as well as improve neuroinflammation and memory. Therefore, we hypothesized...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742665/ https://www.ncbi.nlm.nih.gov/pubmed/36510244 http://dx.doi.org/10.1186/s13030-022-00255-0 |
_version_ | 1784848574635311104 |
---|---|
author | Oka, Takakazu Yamada, Yu Lkhagvasuren, Battuvshin Nakao, Mutsuhiro Nakajima, Ryota Kanou, Masanobu Hiramatsu, Ryuji Nabeshima, Yo-ichi |
author_facet | Oka, Takakazu Yamada, Yu Lkhagvasuren, Battuvshin Nakao, Mutsuhiro Nakajima, Ryota Kanou, Masanobu Hiramatsu, Ryuji Nabeshima, Yo-ichi |
author_sort | Oka, Takakazu |
collection | PubMed |
description | BACKGROUND: Wasabi (Eutrema japonicum) is a common pungent spice used in Japan. 6-Methylsulfinylhexyl isothiocyanate (6-MSITC) found in the rhizome of wasabi has been shown to have anti-inflammatory and antioxidant effects, as well as improve neuroinflammation and memory. Therefore, we hypothesized that these effects would be beneficial for treating myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The present study was conducted to investigate the effectiveness of wasabi extract containing 6-MSITC on ME/CFS in an open-label trial. METHODS: Fifteen patients (3 males, 12 females, 20–58 years old) were orally administered wasabi extract (9.6 mg of 6-MSITC/day) for 12 weeks. The following parameters and test results were compared pre- and post-treatment: performance status (PS), self-rating questionnaires, pressure pain threshold (PPT) on the occiput, Trail Making test-A (TMT-A), and hemodynamic patterns determined by an active standing test. RESULTS: After treatment with 6-MSITC, PS improved significantly (p = 0.001). Although the scores on the 11-item Chalder Fatigue scale (CFS-11) and numerical rating scale (NRS) of fatigue did not show significant changes, subjective symptoms improved significantly, including headache frequency (4.1 to 3.0 times/week, p = 0.001) and myalgia (4.1 to 2.4 times/week, p = 0.019), NRS brain fog scores (5.7 to 4.5, p = 0.011), difficulty finding appropriate words (4.8 to 3.7, p = 0.015), photophobia (4.8 to 3.5, p = 0.008), and the Profile of Mood Status vigor score (46.9 to 50.0, p = 0.045). The PPT of the right occiput (17.3 to 21.3 kPa, p = 0.01) and TMT-A scores (53.0 to 38.1 s, p = 0.007) also changed, suggesting reduced pain sensitivity, and improved cognitive function, respectively. Orthostatic patterns determined by a standing test did not show remarkable changes. There were no serious adverse reactions. CONCLUSION: This study suggests that 6-MSITC improves PS as well as subjective symptoms such as pain and cognitive dysfunction, and psychological vitality of patients with ME/CFS. It also improved cognitive performance and increased pain thresholds in these patients. 6-MSITC may be a promising therapeutic option especially for improving cognitive dysfunction associated with ME/CFS. |
format | Online Article Text |
id | pubmed-9742665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97426652022-12-12 Clinical effects of wasabi extract containing 6-MSITC on myalgic encephalomyelitis/chronic fatigue syndrome: an open-label trial Oka, Takakazu Yamada, Yu Lkhagvasuren, Battuvshin Nakao, Mutsuhiro Nakajima, Ryota Kanou, Masanobu Hiramatsu, Ryuji Nabeshima, Yo-ichi Biopsychosoc Med Research BACKGROUND: Wasabi (Eutrema japonicum) is a common pungent spice used in Japan. 6-Methylsulfinylhexyl isothiocyanate (6-MSITC) found in the rhizome of wasabi has been shown to have anti-inflammatory and antioxidant effects, as well as improve neuroinflammation and memory. Therefore, we hypothesized that these effects would be beneficial for treating myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The present study was conducted to investigate the effectiveness of wasabi extract containing 6-MSITC on ME/CFS in an open-label trial. METHODS: Fifteen patients (3 males, 12 females, 20–58 years old) were orally administered wasabi extract (9.6 mg of 6-MSITC/day) for 12 weeks. The following parameters and test results were compared pre- and post-treatment: performance status (PS), self-rating questionnaires, pressure pain threshold (PPT) on the occiput, Trail Making test-A (TMT-A), and hemodynamic patterns determined by an active standing test. RESULTS: After treatment with 6-MSITC, PS improved significantly (p = 0.001). Although the scores on the 11-item Chalder Fatigue scale (CFS-11) and numerical rating scale (NRS) of fatigue did not show significant changes, subjective symptoms improved significantly, including headache frequency (4.1 to 3.0 times/week, p = 0.001) and myalgia (4.1 to 2.4 times/week, p = 0.019), NRS brain fog scores (5.7 to 4.5, p = 0.011), difficulty finding appropriate words (4.8 to 3.7, p = 0.015), photophobia (4.8 to 3.5, p = 0.008), and the Profile of Mood Status vigor score (46.9 to 50.0, p = 0.045). The PPT of the right occiput (17.3 to 21.3 kPa, p = 0.01) and TMT-A scores (53.0 to 38.1 s, p = 0.007) also changed, suggesting reduced pain sensitivity, and improved cognitive function, respectively. Orthostatic patterns determined by a standing test did not show remarkable changes. There were no serious adverse reactions. CONCLUSION: This study suggests that 6-MSITC improves PS as well as subjective symptoms such as pain and cognitive dysfunction, and psychological vitality of patients with ME/CFS. It also improved cognitive performance and increased pain thresholds in these patients. 6-MSITC may be a promising therapeutic option especially for improving cognitive dysfunction associated with ME/CFS. BioMed Central 2022-12-12 /pmc/articles/PMC9742665/ /pubmed/36510244 http://dx.doi.org/10.1186/s13030-022-00255-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Oka, Takakazu Yamada, Yu Lkhagvasuren, Battuvshin Nakao, Mutsuhiro Nakajima, Ryota Kanou, Masanobu Hiramatsu, Ryuji Nabeshima, Yo-ichi Clinical effects of wasabi extract containing 6-MSITC on myalgic encephalomyelitis/chronic fatigue syndrome: an open-label trial |
title | Clinical effects of wasabi extract containing 6-MSITC on myalgic encephalomyelitis/chronic fatigue syndrome: an open-label trial |
title_full | Clinical effects of wasabi extract containing 6-MSITC on myalgic encephalomyelitis/chronic fatigue syndrome: an open-label trial |
title_fullStr | Clinical effects of wasabi extract containing 6-MSITC on myalgic encephalomyelitis/chronic fatigue syndrome: an open-label trial |
title_full_unstemmed | Clinical effects of wasabi extract containing 6-MSITC on myalgic encephalomyelitis/chronic fatigue syndrome: an open-label trial |
title_short | Clinical effects of wasabi extract containing 6-MSITC on myalgic encephalomyelitis/chronic fatigue syndrome: an open-label trial |
title_sort | clinical effects of wasabi extract containing 6-msitc on myalgic encephalomyelitis/chronic fatigue syndrome: an open-label trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742665/ https://www.ncbi.nlm.nih.gov/pubmed/36510244 http://dx.doi.org/10.1186/s13030-022-00255-0 |
work_keys_str_mv | AT okatakakazu clinicaleffectsofwasabiextractcontaining6msitconmyalgicencephalomyelitischronicfatiguesyndromeanopenlabeltrial AT yamadayu clinicaleffectsofwasabiextractcontaining6msitconmyalgicencephalomyelitischronicfatiguesyndromeanopenlabeltrial AT lkhagvasurenbattuvshin clinicaleffectsofwasabiextractcontaining6msitconmyalgicencephalomyelitischronicfatiguesyndromeanopenlabeltrial AT nakaomutsuhiro clinicaleffectsofwasabiextractcontaining6msitconmyalgicencephalomyelitischronicfatiguesyndromeanopenlabeltrial AT nakajimaryota clinicaleffectsofwasabiextractcontaining6msitconmyalgicencephalomyelitischronicfatiguesyndromeanopenlabeltrial AT kanoumasanobu clinicaleffectsofwasabiextractcontaining6msitconmyalgicencephalomyelitischronicfatiguesyndromeanopenlabeltrial AT hiramatsuryuji clinicaleffectsofwasabiextractcontaining6msitconmyalgicencephalomyelitischronicfatiguesyndromeanopenlabeltrial AT nabeshimayoichi clinicaleffectsofwasabiextractcontaining6msitconmyalgicencephalomyelitischronicfatiguesyndromeanopenlabeltrial |